Tamoxifen in breast cancer survivors with COVID 19: stop or go?

Karacin, Cengiz; Karacin, Pinar; Ergun, Yakup

Karacin, Cengiz; Karacin, Pinar; Ergun, Yakup.

Karacin C; Department of Medical Oncology, Recep Tayyip Erdogan University, Rize, Turkey. cengizkaracin@yahoo.com.
Karacin P; Department of Gynecology and Obstetrics, Recep Tayyip Erdogan University, Rize, Turkey.
Ergun Y; Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey.

Med Oncol ; 38(4): 42, 2021 03 17.

Article in English | MEDLINE | ID: covidwho-1137182

Subject(s)

Antineoplastic Agents, Hormonal/therapeutic use; Breast Neoplasms/drug therapy; COVID-19/complications; Tamoxifen/therapeutic use; Breast/drug effects; Breast/virology; Breast Neoplasms/virology; COVID-19/virology; Cancer Survivors; Female; Humans; Venous Thromboembolism/etiology; Venous Thromboembolism/virology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Antineoplastic Agents, Hormonal / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Female / Humans Language: English Journal: Med Oncol Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: S12032-021-01492-z

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google